Page 206 - Read Online

Hong et al. Auto-reactive B cells in MuSK MG

was no difference between immunosuppressed and Ethics approval
non-immunosuppressed patients either. However, the This article does not contain any studies with human
plasma B-cell activating factor (BAFF) levels were participants or animals.
significantly increased in MuSK MG patients; another
main finding of this study is that in vitro stimulation REFERENCES
of peripheral blood mononuclear cells resulted in
lower percentages of B10 cells in MuSK MG patients 1. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent
compared to controls. A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients

with myasthenia gravis without acetylcholine receptor antibodies. Nat
Despite the limitations of small number of patients and Med 2001;7:365-8.
heterogeneous treatments, this study provides novel 2. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to
insights and understanding of the immunopathology low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
of MuSK MG. First, this study supports the emerging Ann Neurol 2011;69:418-22.
pathogenic role of BAFF which is a cytokine essential 3. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA,
for the survival and differentiation of B cells. A clinical Xiong WC, Lisak RP, Tzartos SJ, Mei L. Autoantibodies to lipoprotein-
trial of belimumab, the monoclonal antibody that related protein 4 in patients with double-seronegative myasthenia gravis.
targets BAFF, is currently in progress for MG patients. Arch Neurol 2012;69:445-51.
It will be interesting to see if the drug is effective for 4. Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B,
MuSK MG which is often refractory to conventional Melms A, Kröger S. Anti-LRP4 autoantibodies in AChR- and MuSK-
immunosuppressive treatment. Second, B10 cells are antibody-negative myasthenia gravis. J Neurol 2012;259:427-35.
recently characterized regulatory subset of B cells 5. Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak
producing IL-10. With no change in Treg frequency RP, Mei L. Autoantibodies to agrin in myasthenia gravis patients. PLoS
and function, the reduced B10 cells observed in this One 2014;9:e91816.
study suggests a potential mechanism of breakdown 6. Oh SJ. Muscle-specific receptor tyrosine kinase antibody positive
in the immune tolerance in MuSK MG. Future myasthenia gravis current status. J Clin Neurol 2009;5:53-64.
[9]
studies of larger number of patients would help 7. Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR,
further elucidate the precise immunobiology of this Detmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M, Martinez-
rare autoimmune disease. Martinez P, De Baets MH, van der Maarel SM, Verschuuren JJ. Muscle-
specific kinase myasthenia gravis IgG4 autoantibodies cause severe
Financial support and sponsorship neuromuscular junction dysfunction in mice. Brain 2012;135:1081-101.
Nil. 8. Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard
JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ. Characterization
Conflicts of interest of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol
There are no conflicts of interest. Neuroimmunol Neuroinflamm 2015;2:e77.
9. Yi JS, Guidon A, Sparks S, Osborne R, Juel VC, Massey JM, Sanders
Patient consent DB, Weinhold KJ, Guptill JT. Characterization of CD4 and CD8 T cell
No patient involved. responses in MuSK myasthenia gravis. J Autoimmun 2014;52:130-8.

Neuroimmunology and Neuroinflammation ¦ Volume 3 ¦ August 31, 2016 197